PSTV
- Plus Therapeutics, Inc.
()
Overview
Company Summary
Plus Therapeutics, Inc. (PSTV) is a biotechnology company focused on developing innovative and personalized treatments for cancer. The company's primary goal is to improve patient outcomes by developing targeted therapies that address unmet medical needs in various types of cancers.
PSTV uses its proprietary technology platform, called "RNL," which stands for RadioNoise Low-intensity Extracorporeal Pulsation, to develop its therapeutic offerings. RNL is a unique drug delivery technology that utilizes low-intensity pulses of ultrasound to help optimize the distribution and penetration of cancer-fighting drugs within tumors.
One of Plus Therapeutics' key products is RNL-related DocePLUS, a novel formulation of the chemotherapy drug docetaxel. DocePLUS has shown promising results in preclinical studies and is being evaluated in clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer with limited treatment options.
In addition to its core product pipeline, Plus Therapeutics utilizes its extensive knowledge and experience in drug development to provide contract research services to other pharmaceutical and biotech companies. These services include formulation development, process optimization, and clinical trial manufacturing.
Overall, Plus Therapeutics, Inc. is dedicated to leveraging its innovative drug delivery technology and expertise in cancer therapeutics to develop personalized therapies that can potentially improve outcomes and quality of life for patients battling cancer.